After EMA Approval, Hipra Plans to Seek Authorization for its Vaccine Beyond Europe – Europa Press.

The Catalan pharmaceutical Hipra has announced that it will request the authorization of its vaccine from countries outside Europe once the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) has given its approval to the authorization of its vaccine against Covid-19, known as ‘Bimervax’. Thus, the executive vice president and director of R&D and Registries of the pharmaceutical company, Elia Torroella, together with the director of Hipra’s Human Health Division, Carles Fàbrega, have confirmed it at a press conference. (Source: Hipra (Zoom) )